List of Excipients in Branded Drug CYSTEINE HYDROCHLORIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Baxter Healthcare Corporation	CYSTEINE HYDROCHLORIDE	cysteine hydrochloride	0338-9645	HYDROCHLORIC ACID	2039-03-15
Baxter Healthcare Corporation	CYSTEINE HYDROCHLORIDE	cysteine hydrochloride	0338-9645	SODIUM HYDROXIDE	2039-03-15
Baxter Healthcare Corporation	CYSTEINE HYDROCHLORIDE	cysteine hydrochloride	0338-9645	WATER	2039-03-15

Cysteine Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: September 26, 2026

Cysteine hydrochloride is a high-value pharmaceutical amino-acid ingredient with its strongest commercial position in parenteral nutrition, especially neonatal and pediatric formulations. Its main value is functional: it supplies cysteine, improves amino-acid composition, and can support formulation stability in selected products. The commercial opportunity is concentrated in sterile injectable supply, pediatric nutrition, hospital compounding, and specialized formulation services rather than in conventional oral excipient markets.

The product has limited conventional patent protection because cysteine hydrochloride is an old, naturally occurring molecule. Competitive advantage depends on regulatory status, sterile manufacturing, quality consistency, impurity control, container-closure compatibility, supply reliability, and hospital adoption. In the United States, the FDA-approved product Elcys provides the clearest commercial benchmark for cysteine hydrochloride injection. [1]

What is cysteine hydrochloride used for in pharmaceutical formulations?

Cysteine hydrochloride is primarily used as a source of cysteine in compounded or manufactured parenteral nutrition. It may also have formulation utility as a reducing agent or oxygen-sensitive stabilizing component, although its suitability depends on the drug substance, pH, oxidation profile, and route of administration.

Primary pharmaceutical applications

Application	Commercial relevance	Key formulation role
Neonatal parenteral nutrition	High	Provides cysteine for premature and full-term infants
Pediatric parenteral nutrition	High	Supplements amino-acid solutions when endogenous synthesis is limited
Adult parenteral nutrition	Moderate	Supports specialized nutrition protocols
Hospital pharmacy compounding	High	Used in individualized nutrition admixtures
Reducing-agent applications	Selective	May limit oxidation in compatible formulations
Oral solid dosage forms	Low	Cysteine is more often considered an active nutrient or formulation component
Biologic formulations	Selective	Potential redox utility, subject to compatibility and stability data
Cosmetic and personal-care formulations	Separate market	Used in hair and skin products, generally outside pharmaceutical approval pathways

Cysteine is considered conditionally essential in premature infants because endogenous production may be inadequate. The FDA labeling for Elcys identifies cysteine hydrochloride injection as an amino-acid additive to parenteral nutrition solutions for pediatric patients, particularly those receiving total parenteral nutrition. [1]

What is the regulatory status of cysteine hydrochloride injection?

Elcys is the principal FDA-approved cysteine hydrochloride injection product in the United States. The FDA approved Elcys on May 29, 2019, for use as an additive to amino-acid solutions in pediatric patients receiving total parenteral nutrition. The labeled strength is 50 mg/mL of cysteine hydrochloride. [1]

FDA product profile

Regulatory attribute	Elcys status
Active ingredient	Cysteine hydrochloride
Strength	50 mg/mL
Dosage form	Injection
Route	Intravenous admixture use
Indication	Additive to amino-acid solutions in pediatric parenteral nutrition
Approval date	May 29, 2019
FDA pathway	NDA approval
Primary market	Hospitals, neonatal intensive-care units, pediatric nutrition services
Product type	Prescription sterile injectable

Cysteine hydrochloride injection is generally not administered as a standalone therapeutic infusion. The product is added to amino-acid solutions or total parenteral nutrition admixtures under controlled pharmacy or manufacturing procedures.

The product must be distinguished from cysteine as a dietary supplement, L-cysteine used in food processing, and cysteine-containing pharmaceutical excipients. Regulatory status, manufacturing controls, labeling, and permitted use differ across those categories.

What excipient strategy is most attractive for cysteine hydrochloride?

The strongest strategy is to position cysteine hydrochloride as a regulated functional ingredient for sterile compounding and parenteral nutrition rather than as a low-price commodity excipient.

1. Neonatal and pediatric nutrition strategy

This is the highest-value segment. Premature infants have a greater clinical need for cysteine supplementation, while neonatal intensive-care units require reliable sterile products with predictable assay and impurity profiles.

Commercial differentiation can focus on:

• Sterile ready-to-use presentations
• Low-particulate and low-endotoxin specifications
• Small-volume containers suitable for individualized dosing
• Compatibility data with amino-acid solutions and trace elements
• Shelf-life data after dilution or admixture
• Barcoded packaging for hospital pharmacy workflows
• Supply continuity during injectable shortages

The value proposition is operational as much as chemical. Hospitals pay for availability, validated quality, and reduced compounding risk.

2. Premixed parenteral nutrition strategy

A manufacturer could develop premixed cysteine-containing amino-acid or parenteral nutrition products. This approach may reduce pharmacy labor and dosing variability, but it creates a more complex regulatory and stability program.

Key development questions include:

• Cysteine stability during terminal sterilization
• Oxidation to cystine
• Interaction with calcium, phosphate, trace elements, and vitamins
• Container adsorption or leachables
• pH drift during storage
• Particulate formation after admixture
• Compatibility with automated compounding systems

A premixed product may obtain higher commercial value than bulk cysteine hydrochloride because it incorporates formulation know-how and hospital workflow benefits.

3. Excipient and stabilizer applications

Cysteine hydrochloride can be evaluated as a reducing agent in formulations where oxidation affects product quality. This opportunity is more selective than parenteral nutrition because cysteine can also create new risks:

• It may oxidize to cystine.
• It can alter pH and ionic strength.
• It can react with electrophilic drug substances.
• It may affect protein folding or aggregation.
• It can create odor or color changes.
• It may complicate analytical methods.

A formulation developer should treat cysteine hydrochloride as a functional excipient candidate requiring product-specific compatibility data. It should not be assumed to be a universally acceptable antioxidant.

What formulations are protected by cysteine hydrochloride intellectual property?

The molecule itself has limited composition-of-matter protection. Cysteine hydrochloride has been known and used in pharmaceutical and nutritional applications for decades. The commercial IP opportunity is therefore concentrated in formulation, manufacturing, delivery, and use claims.

Potentially protectable areas

IP category	Potential strength	Commercial use
Cysteine hydrochloride composition	Low	Generally weak because of longstanding public knowledge
Sterile injectable formulation	Moderate	May protect concentration, pH, stabilizers, or container system
Pediatric parenteral nutrition use	Moderate	May protect dosing or patient-specific administration methods
Premixed nutrition formulation	Moderate to strong	Depends on composition and unexpected stability results
Oxidation-control formulation	Moderate	Requires credible technical effect
Container-closure system	Moderate	Can protect oxygen-control or adsorption mitigation
Manufacturing process	Moderate	Useful where impurity and sterility control are difficult to reproduce
Automated compounding workflow	Selective	May support device or software-linked claims

Patent claims directed only to cysteine hydrochloride in a conventional amino-acid solution would face substantial prior-art risk. More defensible claims would require a defined concentration range, unusual stability result, specific patient population, container system, or manufacturing condition.

When does cysteine hydrochloride lose exclusivity?

Cysteine hydrochloride does not have a single molecule-level exclusivity date comparable to a recently approved small-molecule drug. The underlying substance is old, and market exclusivity depends on the individual product, regulatory pathway, patent filings, and approval date.

For Elcys, the relevant distinction is between FDA regulatory exclusivity and patent protection:

Exclusivity category	Relevance to cysteine hydrochloride injection
New chemical entity exclusivity	Not expected for an old amino acid
Orphan-drug exclusivity	Not the primary basis identified for the product
New-product or clinical exclusivity	Must be assessed from FDA approval records
Formulation patents	Product-specific and claim-dependent
Manufacturing patents	Product-specific
Orange Book listing	Depends on listed patents for the approved NDA
Generic competition	Requires ANDA approval and pharmaceutical equivalence

A competitor can still face meaningful market barriers without strong patents. Sterile injectable production, validated fill-finish capacity, FDA inspection readiness, and reliable hospital distribution can delay entry even when the active ingredient is off-patent.

What is the Orange Book status of cysteine hydrochloride products?

The Orange Book must be reviewed at the product and NDA level. The relevant question is not whether cysteine hydrochloride appears in the Orange Book as a chemical substance, but whether the approved product has listed patents and whether those patents cover the product, formulation, or method of use.

For a cysteine hydrochloride injection:

1. Identify the approved NDA and active ingredient listing.
2. Review any patent numbers listed by the NDA holder.
3. Check expiration dates and pediatric exclusivity extensions.
4. Determine whether listed patents are product, formulation, or method-of-use patents.
5. Assess whether an ANDA applicant would need a Paragraph IV certification.

Public sources should include the FDA Orange Book, FDA approval letters, the approved product label, and relevant court dockets. [1, 2]

What Paragraph IV challenges and generic entry risks exist?

A generic cysteine hydrochloride injection could create significant price pressure if it achieves pharmaceutical equivalence, sterility assurance, reliable supply, and hospital formulary acceptance.

Generic entry scenarios

Scenario	Likely commercial effect
One approved generic	Moderate price erosion and increased contracting pressure
Multiple injectable generics	High price erosion, especially for bulk hospital contracts
Generic with supply interruptions	Branded or authorized product may retain premium pricing
Ready-to-use competitor	May compete on workflow rather than unit price
Premixed nutrition competitor	Could shift value from active ingredient to total admixture economics
Compounding-pharmacy substitution	May affect demand where state and federal requirements permit

A Paragraph IV challenge would likely focus on any Orange Book-listed formulation or method-of-use patent. A challenger could argue that the claims are anticipated or obvious based on established cysteine use in parenteral nutrition. The NDA holder’s stronger defenses would involve unexpected stability, a specific sterile formulation, container-closure performance, or clinically meaningful pediatric dosing data.

The absence of a prominent public litigation record does not eliminate future challenge risk. Injectable products can attract abbreviated applications after commercial demand, procurement awards, or supply shortages become clear.

How strong is the patent estate for cysteine hydrochloride?

The underlying patent estate is weak from a composition standpoint and potentially moderate for product-specific implementation.

Patent-strength assessment

• Composition of matter: weak.
• Conventional use in parenteral nutrition: weak to moderate, depending on claim scope.
• Pediatric dosing methods: moderate if supported by approved labeling and specific dosing limitations.
• Stable sterile formulation: moderate if the formulation has non-obvious stability or impurity-control results.
• Packaging and oxygen protection: moderate.
• Manufacturing process: moderate where impurity reduction or sterility assurance is difficult.
• Delivery device: potentially strong if the device improves dosing accuracy or reduces contamination.
• Premixed formulation: potentially strong if the product solves a documented compatibility or shelf-life problem.

Trade secrets may be more valuable than patents for sterile manufacturing, oxygen control, raw-material qualification, release testing, and container handling. A company should consider a mixed IP model: narrow patents for visible product attributes and trade-secret protection for process parameters.

What manufacturing barriers affect cysteine hydrochloride commercialization?

The key barriers are not synthesis alone. They are pharmaceutical-grade control and sterile product execution.

Critical manufacturing controls

• Correct stereochemical form, generally L-cysteine hydrochloride
• Control of cystine and oxidation-related impurities
• Assay and water-content consistency
• Bioburden and endotoxin control
• Sterile filtration or terminal sterilization validation
• Oxygen exposure during processing and filling
• Container-closure integrity
• Particulate control
• Extractables and leachables assessment
• Stability after dilution into parenteral nutrition
• Lot-to-lot supply consistency

Cysteine is oxidation-sensitive. Raw-material handling, solution preparation, nitrogen overlay, fill-finish conditions, and storage temperature can affect cystine formation and product quality. These controls create barriers for manufacturers without established sterile injectable infrastructure.

Which companies and channels are positioned in the market?

The market includes branded sterile-injection suppliers, generic injectable manufacturers, contract development and manufacturing organizations, parenteral nutrition manufacturers, and hospital compounding pharmacies.

Commercial channels

1. Hospital direct purchasing
2. Group purchasing organizations
3. Specialty pharmaceutical distributors
4. Home-infusion providers
5. Pediatric and neonatal nutrition programs
6. Outsourcing facilities and compounding pharmacies
7. International distributors for hospital injectables

A supplier with an approved sterile product can compete through regulatory credibility and shortage resilience. A bulk ingredient supplier competes primarily on pharmacopeial quality, qualification support, and supply reliability. A CDMO can capture value by developing cysteine-containing admixtures for third-party sponsors.

What licensing deals could create commercial value?

The most practical licensing structures involve formulation and manufacturing capabilities rather than rights to the cysteine molecule.

Potential deal structures

Deal type	Licensor contribution	Commercial rationale
Sterile product license	Approved injection and regulatory dossier	Fast market entry for regional partner
Formulation license	Stable premixed nutrition composition	Expands product portfolio
CDMO agreement	Sterile filling and analytical package	Avoids capital-intensive manufacturing buildout
Hospital supply agreement	Reserved inventory and shortage protection	Supports premium contracting
Regional distribution license	Regulatory registration and channel access	Expands outside the U.S.
Co-development agreement	Pediatric nutrition product development	Shares clinical and regulatory costs
Device partnership	Prefilled or closed-system delivery	Reduces contamination and dosing risks

A licensee should assess whether rights cover the active product, formulation patents, regulatory dossiers, trademarks, manufacturing know-how, and territory. A license limited to the chemical ingredient has little strategic value because cysteine hydrochloride is broadly available from multiple sources.

How does cysteine hydrochloride compare with competing formulation approaches?

Approach	Advantages	Limitations
Cysteine hydrochloride injection added to amino-acid solution	Flexible dosing and established workflow	Requires pharmacy manipulation
Premixed cysteine-containing nutrition	Lower compounding burden	More complex stability and inventory management
Cysteine-free nutrition	Simpler formulation	May be less suitable for premature infants
Oral cysteine supplementation	Non-sterile and potentially lower cost	Not suitable when enteral delivery is unavailable
Alternative sulfur amino-acid strategies	May support nutrition design	May not provide equivalent clinical or regulatory positioning
Hospital-compounded cysteine solution	Customizable	Higher quality and contamination risk

The principal competitive question is whether the buyer values ingredient price or total pharmacy-system cost. In neonatal nutrition, a ready-to-use or highly reliable sterile product can command value because product failures affect clinical operations and inventory planning.

What revenue exposure and commercial upside exist?

Public revenue disclosure for cysteine hydrochloride products is limited. The opportunity is best evaluated through market drivers rather than unsupported product-sales estimates.

Demand drivers

• Growth in neonatal intensive-care capacity
• Greater standardization of pediatric parenteral nutrition
• Injectable drug shortages
• Hospital preference for qualified sterile suppliers
• Expansion of home parenteral nutrition
• Outsourcing of sterile compounding
• Demand for premixed or ready-to-use nutrition products
• Increased regulatory scrutiny of compounded sterile preparations

Revenue risks

• Low active-ingredient cost relative to sterile manufacturing cost
• Generic price competition
• Limited patient population for labeled pediatric use
• Hospital purchasing concentration
• Substitution by pharmacy-compounded products
• Stability constraints in premixed bags
• Dependence on a small number of qualified facilities
• Procurement decisions based on contract price rather than formulation value

The strongest return profile is likely in an integrated product offering that combines cysteine hydrochloride, sterile presentation, compatibility data, pharmacy workflow support, and supply guarantees.

What geographic markets offer the best opportunities?

The United States offers the clearest opportunity for an FDA-regulated cysteine hydrochloride injection because of its established neonatal nutrition market and formal drug shortage and outsourcing framework.

Europe, Canada, Japan, Australia, and emerging markets may offer opportunities through hospital nutrition products, but regulatory classification differs. A product may be regulated as a medicinal product, hospital preparation, nutrition component, or compounded sterile product depending on jurisdiction.

Geographic strategy

• United States: pursue NDA, ANDA, 505(b)(2), or contract manufacturing opportunities.
• European Union: assess national authorization and centralized or decentralized pathways.
• Canada: evaluate drug identification and sterile injectable requirements.
• Japan: assess local clinical, quality, and import requirements.
• Emerging markets: prioritize supply reliability, local registration, and hospital tenders.

A global strategy should protect the brand, formulation know-how, manufacturing process, and regulatory dossier separately in each major market.

Key Takeaways

• Cysteine hydrochloride has its strongest pharmaceutical role in pediatric and neonatal parenteral nutrition.
• The molecule has limited composition-of-matter patent value because it is old and widely known.
• Commercial protection comes from sterile manufacturing, quality systems, formulation stability, packaging, and supply reliability.
• Elcys is the central U.S. regulatory benchmark, with FDA approval dated May 29, 2019.
• Premixed nutrition products and ready-to-use sterile formats offer greater differentiation than bulk cysteine hydrochloride.
• Generic entry could produce material price erosion, but sterile manufacturing and hospital qualification requirements remain meaningful barriers.
• A licensing strategy should target approved products, formulation technology, manufacturing know-how, or distribution rights rather than the molecule itself.
• The strongest commercial opportunity is an integrated pediatric nutrition product with validated compatibility, controlled oxidation, and reliable hospital supply.

FAQs About Cysteine Hydrochloride Pharmaceutical Commercialization

Is cysteine hydrochloride an active pharmaceutical ingredient or an excipient?

It can be either, depending on the product. In Elcys, cysteine hydrochloride is the labeled active ingredient and amino-acid source. In another drug formulation, it may be evaluated as a functional excipient or reducing agent.

Can cysteine hydrochloride be used in biologic formulations?

Potentially, but use is product-specific. Oxidation control, protein aggregation, disulfide chemistry, pH, and analytical compatibility must be evaluated before regulatory qualification.

Does cysteine hydrochloride require sterile manufacturing?

Bulk pharmaceutical-grade cysteine hydrochloride does not necessarily require sterile manufacture. An injectable cysteine hydrochloride product does require validated sterile manufacturing, container-closure integrity, endotoxin control, and particulate control.

What is the main commercial risk for a cysteine hydrochloride injection?

The principal risk is price competition after generic or competing sterile products enter the market. Supply interruptions, failed inspections, oxidation-related quality issues, and hospital contract concentration are also material risks.

Can a company patent a new cysteine hydrochloride formulation?

Yes, a formulation may be patentable if it has novelty and non-obvious technical advantages, such as improved stability, reduced cystine formation, extended admixture shelf life, or a specialized container system. The patentability of the molecule itself is substantially weaker.

References

1. U.S. Food and Drug Administration. (2019). Elcys (cysteine hydrochloride injection) prescribing information. FDA.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
3. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: Cysteine hydrochloride monograph. USP.
4. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. FDA.
5. U.S. Food and Drug Administration. (2023). Parenteral nutrition products and sterile compounding guidance. FDA.